Track topics on Twitter Track topics that are important to you
University of Sunderland research into nanoparticle-based drug delivery systems is supporting the development of a new drug-candidate for treatment of triple negative breast cancer.The RAN-blocking peptide drug is being developed by a university consortium, led by Professor Mohamed El-Tanani at the University of Bradford and includes Ulster University, Queen’s University Belfast and University of Sunderland. Dr Ahmed Faheem at University of Sunderland Faculty of Health Sciences and Wellbeing is contributing his expertise in biodegradable nanoparticles for peptide delivery to engineer a series of nanoparticle to encapsulate the peptide. These peptide loaded nanoparticles have been shown, in vitro, to enter triple negative breast cancer cells, block RAN and reduce cell growth growth. The consortium is now developing in vivo models of triple negative breast cancer to allow further pre-clinical testing of the nanoparticles.
Original Article: Nanoparticle Drug Delivery at University of SunderlandNEXT ARTICLE
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals. <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...